DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,259,433 | -27.3% | 254,941 | +3.9% | 1.02% | -15.2% |
| Q2 2023 | $7,238,537 | +28.3% | 245,291 | +0.2% | 1.21% | +11.3% |
| Q1 2023 | $5,641,344 | -16.8% | 244,850 | +0.4% | 1.08% | -17.4% |
| Q4 2022 | $6,781,469 | -9.2% | 243,850 | +0.2% | 1.31% | -10.8% |
| Q3 2022 | $7,468,000 | +25.6% | 243,350 | +20.4% | 1.47% | +22.8% |
| Q2 2022 | $5,948,000 | -10.7% | 202,100 | -2.4% | 1.20% | +1.3% |
| Q1 2022 | $6,662,000 | -21.2% | 207,100 | +9.2% | 1.18% | -7.1% |
| Q4 2021 | $8,456,000 | +31.5% | 189,600 | +48.7% | 1.27% | +137.9% |
| Q3 2021 | $6,432,000 | +26.1% | 127,500 | +96.2% | 0.54% | +29.5% |
| Q2 2021 | $5,099,000 | +2136.4% | 65,000 | +1525.0% | 0.41% | +2329.4% |
| Q1 2021 | $228,000 | -1.7% | 4,000 | -58.3% | 0.02% | -19.0% |
| Q2 2020 | $232,000 | – | 9,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,705,039 | $343,645,000 | 25.68% |
| Casdin Capital, LLC | 1,500,000 | $66,900,000 | 1.89% |
| Flagship Pioneering Inc. | 2,619,968 | $116,851,000 | 1.81% |
| SECTORAL ASSET MANAGEMENT INC | 189,600 | $8,456,000 | 1.27% |
| Integral Health Asset Management, LLC | 100,000 | $4,460,000 | 1.23% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $239,479,000 | 0.86% |
| Goldstream Capital Management Ltd | 78,418 | $3,497,000 | 0.86% |
| Yiheng Capital Management, L.P. | 335,184 | $14,949,000 | 0.76% |
| GILDER GAGNON HOWE & CO LLC | 2,900,114 | $129,345,000 | 0.74% |
| Artal Group S.A. | 600,000 | $26,760,000 | 0.73% |